Does insurance cover GLP-1s for weight loss?

Insurance covers GLP-1s for weight loss only some of the time, and the answer depends on your type of plan. Commercial plans set their own rules, Medicare pays only through a temporary program that charges $50 a month, and as of mid-October 2026 just 10 state Medicaid programs cover these drugs for obesity, two of them under tight limits. If you aren’t covered, brand-name self-pay prices start at $149 a month.

Coverage at a glance

Commercial insurance: check your plan’s drug list

Each employer or marketplace plan decides whether to cover GLP-1s for weight loss, and that decision can change at renewal. In Massachusetts, for example, the board that runs state employee health plans (GIC) voted 10-7 to drop weight-loss drug coverage starting with the July 2026 plan year (GBH News).

Call the member number on your card, or look up your plan’s drug list online, and ask:

• Are Wegovy, Zepbound or Foundayo covered for weight management?
• Is prior authorization required, and what are the criteria?
• Does the answer change for another approved use, such as sleep apnea or heart disease?
• What will I pay each month after my deductible?

Prior authorization means your plan wants records from your clinician showing you meet its criteria before it pays. If a request is denied, ask your clinician whether an appeal makes sense.

If your plan does cover the drug, manufacturer savings can cut the cost to as little as $25 a month for Zepbound or Wegovy, with NovoCare capping its savings at $100 a month (NovoCare). People with Medicare, Medicaid or other government coverage can’t use these offers.

Why the reason for the prescription matters

Some GLP-1s are approved for more than weight loss. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity (Zepbound label). Wegovy is approved to lower the risk of heart attack, stroke and cardiovascular death in adults with established cardiovascular disease and obesity or overweight (Wegovy label).

Those uses are often handled differently from weight loss. Medicare sends them through the regular Part D plan, and many state Medicaid programs that don’t cover weight loss still cover GLP-1s for diabetes, heart disease and sleep apnea.

Vineyard’s in-house insurance concierge handles prior authorizations and appeals for its members, though the $150 monthly membership itself can’t be billed to insurance. See our Vineyard review and our list of GLP-1 providers that work with insurance.

Medicare: the $50 GLP-1 Bridge

The Medicare GLP-1 Bridge runs from July 1, 2026, to December 31, 2027. Eligible Part D enrollees pay $50 a month for a weight-loss GLP-1, and that copay doesn’t count toward the Part D out-of-pocket maximum. Low-income subsidies don’t apply to it.

The CMS prior authorization form lists Foundayo, Wegovy (injection, tablets and the higher-dose HD) and the Zepbound KwikPen. It asks your clinician about your BMI, prediabetes, a past heart attack or stroke, peripheral artery disease, heart failure with preserved ejection fraction, uncontrolled high blood pressure and kidney disease at stage 3a or higher. Manufacturers supply these drugs at a $245 net monthly price (KFF).

Medicare’s longer-term plan has shifted. CMS said in April 2026 that the Medicare side of its BALANCE model won’t launch in 2027 and extended the Bridge through 2027 instead (CMS). Our Medicare guide covers eligibility in more detail.

Medicaid: states that cover GLP-1s for obesity

Medicaid coverage for weight loss has been shrinking. KFF counted 13 state programs covering GLP-1s for obesity in January 2026, down from 16 in October 2025, after California, New Hampshire, Pennsylvania and South Carolina ended coverage (KFF). Since then, Utah’s coverage ended June 30, 2026, MassHealth stopped in early July 2026, and Rhode Island ended coverage on October 1, 2026.

These are the state Medicaid programs that cover GLP-1s for obesity as of mid-October 2026, based on state notices compiled by The Rx Index, Michigan Public and Virginia Medicaid. Every one of them requires prior authorization or strict criteria.

In most other states, Medicaid still covers GLP-1s for diabetes, heart disease and sleep apnea, but not for weight loss alone. Connecticut, Louisiana, New Hampshire, New Mexico, North Dakota, Pennsylvania and Texas cover some non-GLP-1 weight-loss drugs instead. California reviews requests for people under 21 case by case, and Pennsylvania keeps an under-21 pathway.

More states could join. CMS’s voluntary BALANCE model lets state Medicaid programs cover GLP-1s for obesity at negotiated prices, and states may join from May 2026 through January 1, 2027, depending on state and manufacturer participation. Indiana announced on July 30, 2026, that it will join, with its start date and eligibility rules still pending (Indiana Capital Chronicle). These rules change often, so confirm with your state Medicaid office or plan before you count on coverage.

If your plan says no

Start with your clinician. If you have a second approved use, such as sleep apnea or established cardiovascular disease, ask whether a prior authorization for that use fits your situation. If coverage still isn’t there, self-pay is the fallback.

Brand-name self-pay prices start at $149 a month for the Wegovy pill, and our guide to GLP-1s without insurance lists every cash option by true monthly cost. Online compounded programs start lower: at the 39 programs we rank, as of October 2026, compounded semaglutide starts at $89 a month at altRx and Enhanced, or at LumiMeds as a promotion (regularly $189).

A compounded GLP-1 is not the brand-name drug and not a generic of it. A compounding pharmacy prepares it, and it isn’t FDA-approved or reviewed by the FDA for safety, effectiveness or quality (FDA). Read our compounded GLP-1 guide before you choose that route.

Most of the cash-pay programs we track accept HSA or FSA payments, including altRx, LumiMeds, Precision Telemed and WellPeps. Our cheapest GLP-1 ranking compares the lowest prices side by side.

The bottom line

Check your plan’s drug list and prior authorization rules before you assume either way. On Medicare, the $50 Bridge runs through 2027; on Medicaid, coverage depends on your state and keeps changing. When the answer is no, compare self-pay options with our cost calculator and talk with a licensed clinician about which drug fits you.